Patient Assistance Programs for Ketamine Therapy
The cost of ketamine therapy — whether IV, Spravato, or compounded oral — can be prohibitive for many patients. Fortunately, several manufacturer programs, non-profit organizations, and institutional resources exist to help qualified patients access treatment at reduced or no cost.
Manufacturer Programs
Spravato Passport (Janssen)
The most significant manufacturer-sponsored program for ketamine therapy is the Spravato Passport, administered by Janssen Pharmaceuticals for Spravato (esketamine) patients.
Copay Assistance (for commercially insured patients):
- Eligible patients with commercial insurance that covers Spravato may reduce their out-of-pocket cost to as little as $10 per treatment session
- No income requirements for the copay card component (see our insurance coverage guide for broader coverage strategies)
- Applies to deductibles, coinsurance, and copayments
- Annual benefit limits may apply; check current program terms
How to Enroll:
- Contact your REMS-certified healthcare setting to confirm they participate in the Passport program
- Complete patient enrollment online at spravato.com or through the clinic
- Receive your Passport program identifier
- Your clinic applies the benefit at each treatment session
Eligibility Limitations:
- NOT available for patients covered by Medicare, Medicaid, or other federal/state programs (federal law prohibits manufacturer copay assistance for government program beneficiaries)
- Must have a commercially insured patient with actual Spravato coverage
Free Drug Program (Janssen CarePath):
For patients who are uninsured or whose insurance does not cover Spravato, Janssen CarePath may provide Spravato at no cost or reduced cost based on financial need:
- Income-based eligibility (generally up to 400% of federal poverty level, though criteria may change)
- Application required with proof of income and documentation of insurance status
- Contact: 1-844-4SPRAVO (1-844-477-2860)
Non-Profit Organizations
NAMI (National Alliance on Mental Illness)
NAMI does not provide direct drug assistance but maintains the NAMI HelpLine (1-800-950-NAMI) and resource database that can connect patients with:
- State pharmaceutical assistance programs
- Charitable pharmacies
- Local financial assistance programs
NAMI also provides advocacy support for patients appealing insurance denials.
Mental Health America (MHA)
MHA's affiliate network (state and local affiliates) sometimes has access to local financial assistance resources, emergency funds for mental health care, or connections to reduced-cost clinical services. Contact your local MHA affiliate for region-specific resources.
Patient Advocate Foundation
The Patient Advocate Foundation (patientadvocate.org) offers:
- Case management services to help navigate insurance coverage
- Co-pay relief assistance through its Co-Pay Relief Program (for patients with specific diagnoses)
- Financial aid from their national financial hardship fund
- Appeals assistance for insurance denials
Their services are free to patients and funded through grants. Not all diagnoses qualify for co-pay relief at any given time; current qualifying diagnoses are listed on their website.
RxHope, RxAssist, and NeedyMeds
These organizations maintain searchable databases of patient assistance programs across many pharmaceutical manufacturers:
- RxAssist.org: Comprehensive database of manufacturer PAPs with eligibility criteria
- NeedyMeds.org: Searchable database of drug assistance programs and disease-specific funds
- RxOutreach.org: Prescription assistance for lower-income patients
While ketamine-specific programs may not always be listed, these databases are useful for identifying assistance for concurrent medications.
State Pharmaceutical Assistance Programs (SPAPs)
Many states have pharmaceutical assistance programs for specific populations:
- Elderly patients: Many states have programs for Medicare beneficiaries to reduce medication costs
- Low-income individuals: Some states extend medication assistance beyond Medicaid
Eligibility and covered drugs vary by state. Contact your state's department of health or aging services to inquire about available programs.
Sliding-Scale and Community Mental Health
Community Mental Health Centers (CMHCs)
Federally-funded CMHCs provide mental health services on a sliding-fee scale based on income. While most CMHCs do not yet offer ketamine therapy specifically, some that have integrated medication management may be willing to prescribe ketamine tablet for appropriate patients at reduced cost.
Contact your local CMHC to ask about their services and whether they have providers with ketamine prescribing experience.
Federally Qualified Health Centers (FQHCs)
FQHCs serve underserved communities on a sliding-scale basis and have access to 340B drug pricing — a federal program that allows qualifying health centers to purchase drugs at significantly reduced prices. If an FQHC has a provider who prescribes ketamine, 340B pricing could potentially reduce compounded ketamine tablet costs.
Institutional and Hospital-Based Resources
Hospital Financial Assistance Programs
For patients receiving ketamine in hospital-based outpatient settings (academic medical centers, hospital-affiliated clinics), most hospitals have charity care or financial assistance programs. These programs may:
- Reduce or eliminate clinical fees for eligible patients
- Apply to both the clinical visit and the drug administration costs in some cases
- Require income verification and application
Contact the financial counselor or patient financial services department at the treating facility.
Academic Research Programs
Some academic medical centers conduct research studies on ketamine therapy that provide treatment at reduced or no cost to participants. ClinicalTrials.gov is the primary database for finding active studies. Search for "ketamine" combined with your condition and location to identify ongoing trials.
Participating in research provides:
- Access to treatment (often at no cost)
- Highly monitored, rigorous care
- Contribution to the evidence base that will ultimately improve access for all patients
Strategies for Compounded Ketamine Tablet
For compounded ketamine tablet — where manufacturer assistance programs don't apply — financial strategies include:
FSA/HSA Maximization
Maximize contributions to your FSA (flexible spending account) or HSA (health savings account) to pay for compounded ketamine with pre-tax dollars. At a 22% marginal tax rate, a $500/month drug cost becomes effectively $390/month after tax savings.
Prescription Discount Cards
GoodRx, RxSaver, and similar services can sometimes reduce compounding pharmacy costs, though their applicability to compounded controlled substances varies. Check whether your pharmacy accepts these programs.
Pharmacy Comparison Shopping
As documented in our compounding pharmacies article, ketamine prices vary meaningfully between PCAB-accredited pharmacies. Comparing quotes from 2–3 quality pharmacies can identify meaningful savings.
Telehealth Platform Bundle Pricing
Some telehealth ketamine platforms offer bundled pricing that is more affordable than the sum of separate prescriber and pharmacy costs. For uninsured patients, this can be the most cost-effective access point.
Advocacy for Future Access
For patients frustrated by cost barriers, participating in advocacy efforts can help create systemic change:
- Support NAMI and other mental health advocacy organizations lobbying for ketamine coverage mandates
- Share your story with your insurance company (directly and through appeals)
- Contact state and federal legislators about mental health parity enforcement
- Participate in advocacy efforts through patient communities
The coverage landscape for ketamine is improving — driven partly by patient and clinical advocacy — and continued engagement will accelerate this progress.
References
- StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
- PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
- MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
- MedlinePlus: Esketamine Nasal Spray — National Library of Medicine drug information on FDA-approved Spravato (esketamine) for treatment-resistant depression
- Healthcare.gov: Understanding Costs — Federal marketplace resource explaining insurance terminology and out-of-pocket healthcare costs
Share